T Heise

Summary

Publications

  1. pmc Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitus
    Thomas Rauch
    Boehringer Ingelheim, Ingelheim, Germany
    Diabetes Ther 3:10. 2012
  2. doi request reprint Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes
    T Heise
    Profil, Hellersbergstrasse 9, Neuss, Germany
    Diabetes Obes Metab 15:613-21. 2013
  3. doi request reprint Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes
    T Heise
    Profil Institute for Metabolic Research, Neuss, Germany
    Diabetes Obes Metab 14:944-50. 2012
  4. doi request reprint Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes
    T Heise
    Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany
    Diabetes Obes Metab 14:859-64. 2012
  5. doi request reprint The pharmacokinetic and pharmacodynamic properties of different formulations of biphasic insulin aspart: a randomized, glucose clamp, crossover study
    T Heise
    Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany
    Diabetes Technol Ther 10:479-85. 2008
  6. ncbi request reprint Impact of diabetic nephropathy on pharmacodynamic and Pharmacokinetic properties of insulin in type 1 diabetic patients
    K Rave
    Profil Institute for Metabolic Research, Neuss, Germany
    Diabetes Care 24:886-90. 2001
  7. ncbi request reprint Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes
    O Klein
    Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany
    Diabetes Obes Metab 9:290-9. 2007
  8. doi request reprint Insulin aspart has a shorter duration of action than human insulin over a wide dose-range
    L Nosek
    Profil Institute for Metabolic Research, Neuss, Germany
    Diabetes Obes Metab 15:77-83. 2013
  9. ncbi request reprint Insulin detemir under steady-state conditions: no accumulation and constant metabolic effect over time with twice daily administration in subjects with Type 1 diabetes
    S Bott
    Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany
    Diabet Med 23:522-8. 2006
  10. ncbi request reprint Inhaled insulin as adjunctive therapy in subjects with type 2 diabetes failing oral agents: a controlled proof-of-concept study
    M Hausmann
    Profil Institut für Stoffwechselforschung GmbH, Hellersbergstr 9, Neuss, Germany
    Diabetes Obes Metab 8:574-80. 2006

Collaborators

Detail Information

Publications27

  1. pmc Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitus
    Thomas Rauch
    Boehringer Ingelheim, Ingelheim, Germany
    Diabetes Ther 3:10. 2012
    ..The effects of linagliptin on DPP-4, pharmacodynamic parameters, and glycemic control versus placebo were assessed in patients with inadequately controlled T2DM...
  2. doi request reprint Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes
    T Heise
    Profil, Hellersbergstrasse 9, Neuss, Germany
    Diabetes Obes Metab 15:613-21. 2013
    ..To investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of empagliflozin in patients with type 2 diabetes following oral administration of 10, 25 or 100 mg doses once daily over 28 days...
  3. doi request reprint Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes
    T Heise
    Profil Institute for Metabolic Research, Neuss, Germany
    Diabetes Obes Metab 14:944-50. 2012
    ..This double-blind, two-period, incomplete block cross-over trial investigated the pharmacodynamic and pharmacokinetic properties of IDeg at steady state (SS) in people with type 2 diabetes...
  4. doi request reprint Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes
    T Heise
    Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany
    Diabetes Obes Metab 14:859-64. 2012
    ..Insulin degludec (IDeg) is a new-generation basal insulin with an ultra-long duration of action. We compared the pharmacodynamic (PD) variability of IDeg and insulin glargine (IGlar) under steady-state conditions...
  5. doi request reprint The pharmacokinetic and pharmacodynamic properties of different formulations of biphasic insulin aspart: a randomized, glucose clamp, crossover study
    T Heise
    Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany
    Diabetes Technol Ther 10:479-85. 2008
    ..The new formulations BIAsp 50 and BIAsp 70 contain 50% and 70% soluble IAsp, respectively. We compared the pharmacodynamics (PD) and pharmacokinetics (PK) of BIAsp 30, 50, and 70 and IAsp in a glucose clamp trial...
  6. ncbi request reprint Impact of diabetic nephropathy on pharmacodynamic and Pharmacokinetic properties of insulin in type 1 diabetic patients
    K Rave
    Profil Institute for Metabolic Research, Neuss, Germany
    Diabetes Care 24:886-90. 2001
    ..To quantify pharmacokinetic and pharmacodynamic properties of regular insulin and insulin lispro in type 1 diabetic patients with and without overt diabetic nephropathy...
  7. ncbi request reprint Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes
    O Klein
    Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany
    Diabetes Obes Metab 9:290-9. 2007
    ..This study compared the time-action profiles of the novel albumin-bound basal insulin analogue NN344 with those of insulin detemir and insulin glargine in individuals with type 2 diabetes...
  8. doi request reprint Insulin aspart has a shorter duration of action than human insulin over a wide dose-range
    L Nosek
    Profil Institute for Metabolic Research, Neuss, Germany
    Diabetes Obes Metab 15:77-83. 2013
    ..This study compared late metabolic activity (4-12 and 6-12 h post-dosing) and duration of action (time to reach late half-maximal activity) over a range of doses between insulin aspart (IAsp) and RHI...
  9. ncbi request reprint Insulin detemir under steady-state conditions: no accumulation and constant metabolic effect over time with twice daily administration in subjects with Type 1 diabetes
    S Bott
    Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany
    Diabet Med 23:522-8. 2006
    ....
  10. ncbi request reprint Inhaled insulin as adjunctive therapy in subjects with type 2 diabetes failing oral agents: a controlled proof-of-concept study
    M Hausmann
    Profil Institut für Stoffwechselforschung GmbH, Hellersbergstr 9, Neuss, Germany
    Diabetes Obes Metab 8:574-80. 2006
    ..This controlled proof-of-concept study investigated inhaled insulin (INH) as adjunctive therapy to existing oral antidiabetic agents in subjects with type 2 diabetes...
  11. ncbi request reprint Insulin glulisine: a faster onset of action compared with insulin lispro
    T Heise
    Profil Institut für Stoffwechselforschung, Neuss, Germany
    Diabetes Obes Metab 9:746-53. 2007
    ..This randomized, single-centre, double-blind, crossover study compared the pharmacodynamic and pharmacokinetic properties of two different doses of insulin glulisine (glulisine) and insulin lispro (lispro) in lean to obese subjects...
  12. doi request reprint PROMAXX inhaled insulin: safe and efficacious administration with a commercially available dry powder inhaler
    T Heise
    Profil Institute for Metabolic Research, Neuss, Germany
    Diabetes Obes Metab 11:455-9. 2009
    ..We investigated the pharmacokinetic (PK) and pharmacodynamic (PD) properties of recombinant human insulin inhalation powder (RHIIP), manufactured with PROMAXX technology, which allows formation of uniform protein microspheres...
  13. doi request reprint Pharmacokinetics and linear exposure of AFRESA compared with the subcutaneous injection of regular human insulin
    K Rave
    Profil Institut für Stoffwechselforschung GmbH, Hellerbergstrasse 96, Neuss 41460, Germany
    Diabetes Obes Metab 11:715-20. 2009
    ..The aim of this study was to compare the pharmacokinetic (PK) and pharmacodynamic (PD) parameters of three different inhaled doses of TI with those of subcutaneous (s.c.) RHI...
  14. doi request reprint U-100, pH-Neutral formulation of VIAject(®) : faster onset of action than insulin lispro in patients with type 1 diabetes
    L Heinemann
    Profil Institut für Stoffwechselforschung, Hellersbergstrasse 9, Neuss, Germany
    Diabetes Obes Metab 14:222-7. 2012
    ....
  15. doi request reprint Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin(*)
    U Graefe-Mody
    Boehringer Ingelheim Pharma GmbH and Co KG, Ingelheim, Germany
    Diabetes Obes Metab 13:939-46. 2011
    ....
  16. doi request reprint Continuous glucose monitoring: quality of hypoglycaemia detection
    E Zijlstra
    Profil Institut fu r Stoffwechselforschung GmbH, Hellersbergstrasse 9, 41460 Neuss, Germany
    Diabetes Obes Metab 15:130-5. 2013
    ..To evaluate the accuracy of a (widely used) continuous glucose monitoring (CGM)-system and its ability to detect hypoglycaemic events...
  17. pmc How pharmacokinetic and pharmacodynamic principles pave the way for optimal basal insulin therapy in type 2 diabetes
    S Arnolds
    Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany
    Int J Clin Pract 64:1415-24. 2010
    ..Finally, the necessity of overcoming patient and/or physician barriers to insulin therapy and providing continuing education and training is emphasised...
  18. doi request reprint Pharmacokinetic and pharmacodynamic properties of taspoglutide, a once-weekly, human GLP-1 analogue, after single-dose administration in patients with Type 2 diabetes
    C Kapitza
    Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany
    Diabet Med 26:1156-64. 2009
    ..The study objectives were to evaluate the pharmacokinetic and pharmacodynamic properties, as well as safety and tolerability, of single doses of taspoglutide, a human glucagon-like peptide-1 (GLP-1) analogue...
  19. ncbi request reprint Alternative routes of administration as an approach to improve insulin therapy: update on dermal, oral, nasal and pulmonary insulin delivery
    L Heinemann
    Profil Institute for Metabolic Research, Stresemannallee 6, 41460 Neuss, Germany
    Curr Pharm Des 7:1327-51. 2001
    ..As of to date no serious side effects have been reported from these human trials. In summary, it appear that after several decades of research, for the first time a feasible alternative route for insulin administration is within reach...
  20. ncbi request reprint Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies
    T Heise
    Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany
    Diabetes Obes Metab 9:648-59. 2007
    ..These findings in experimental glucose clamp studies are consistent with observations in clinical trials and support routine once daily use with either analogue, in particular in people with type 2 diabetes...
  21. ncbi request reprint Noninvasive glucose measurement by monitoring of scattering coefficient during oral glucose tolerance tests. Non-Invasive Task Force
    L Heinemann
    Profil Institute for Metabolic Research GmbH, Neuss, Germany
    Diabetes Technol Ther 2:211-20. 2000
    ..In this study, we investigated whether also slower changes in blood glucose, this time induced by an oral glucose load, can also be monitored by this approach...
  22. doi request reprint Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients
    T Heise
    Profil Institut für Stoffwechselforschung GmbH, Hellersbergstrasse, Neuss, Germany
    Diabetes Obes Metab 11:786-94. 2009
    ..To investigate the safety, tolerability, pharmacokinetic and pharmacodynamic properties of multiple oral doses of the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin (BI 1356) in patients with type 2 diabetes mellitus...
  23. doi request reprint Insulin glulisine has a faster onset of action compared with insulin aspart in healthy volunteers
    S Arnolds
    Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany lresearch de
    Exp Clin Endocrinol Diabetes 118:662-4. 2010
    ..Because of its zinc-free formulation insulin glulisine (GLU) might have a faster onset of action than other short-acting analogues. We compared the pharmacokinetics and pharmacodynamics of GLU with those of insulin aspart (ASP)...
  24. ncbi request reprint The pharmacokinetic and pharmacodynamic properties of biphasic insulin Aspart 70 (BIAsp 70) are significantly different from those of biphasic insulin Aspart 30 (BIAsp 30)
    S Bott
    Profil Institut fuer Stoffwechselforschung GmbH, Neuss, Germany
    Exp Clin Endocrinol Diabetes 113:545-50. 2005
    ....
  25. ncbi request reprint Rapid and long-acting analogues as an approach to improve insulin therapy: an evidence-based medicine assessment
    T Heise
    Profil Institute for Metabolic Research, Stresemannallee 6, 41460 Neuss, Germany
    Curr Pharm Des 7:1303-25. 2001
    ..Finally, we review the relevant data concerning the safety aspects of the various analogues, thus allowing the reader to perform an individual risk-benefit-assessment...
  26. ncbi request reprint Impact of smoking on the metabolic action of subcutaneous regular insulin in type 2 diabetic patients
    S Bott
    Profil Institut für Stoffwechselforschung GmbH, D 41460 Neuss, Germany
    Horm Metab Res 37:445-9. 2005
    ....